American Journal of Psychiatry Audio

Release Date

All Episodes

March 2026: Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial

Chelsea Dyan Gober Dykan, M.A. (Tel Aviv University, Israel), joins AJP Audio to discuss a study looking at two versions of attention bias modification with an eye towards a prophylactic impact on developing PTSD in a cohort of combat-bound soldiers. Afterwards, AJP Editor-in-Chi ... Show more

. 33min 17sec

February 2026: Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial

Dr. Ian Kelleher (University of Edinburgh, Scotland) joins AJP Audio to discuss an emulated target trial looking at the prophylactic qualities of doxycycline, an antibiotic, in an adolescent population at risk to develop schizophrenia spectrum disorder. Afterwards, AJP Editor-in- ... Show more

. 29min 58sec

Special Episode: 2025 Articles of Import and Impact

This special episode of AJP Audio brings together the editors of the American Journal Psychiatry and the AJP Residents' Journal to discuss important and impactful articles published in 2025. 00:39 Ned H. Kalin, M.D., discusses "Transcriptomic Analysis of the Human Habenula in Sch ... Show more

. 33min 12sec

January 2026: Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders

Dr. Julia Linke (University of Mainz, Germany) joins AJP Audio to discuss the use of neural efficiency, a measure of brain activity, as a potential biomarker in the treatment of children with anxiety disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to put ... Show more

. 26min 13sec

December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial

Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of p ... Show more

. 22min 12sec